Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimizing fertility potential after surgery for bilateral cryptorchidism using gonadotropin therapy
2019-004458-27Phase 4Terminated
- Sponsor
- Rigshospitalet
- Start
- Dec 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4 trial of gonadorelin in cryptorchidism, sponsored by Rigshospitalet. Primary endpoint: Effect of gonadotropin therapy on fertility potential. Started Dec 2019; status: terminated.
02
Drugs
gonadorelin
03
Conditions
cryptorchidism
Beyond the preview
Go deeper on 2019-004458-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004458-27.